CohBar Inc
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fi… Read more
CohBar Inc (CWBR) - Net Assets
Latest net assets as of June 2023: $9.50 Million USD
Based on the latest financial reports, CohBar Inc (CWBR) has net assets worth $9.50 Million USD as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.51 Million) and total liabilities ($3.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.50 Million |
| % of Total Assets | 76.0% |
| Annual Growth Rate | 36.02% |
| 5-Year Change | -14.64% |
| 10-Year Change | N/A |
| Growth Volatility | 251.37 |
CohBar Inc - Net Assets Trend (2011–2022)
This chart illustrates how CohBar Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CohBar Inc (2011–2022)
The table below shows the annual net assets of CohBar Inc from 2011 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $15.33 Million | -40.13% |
| 2021-12-31 | $25.61 Million | +38.52% |
| 2020-12-31 | $18.49 Million | +127.20% |
| 2019-12-31 | $8.14 Million | -54.70% |
| 2018-12-31 | $17.96 Million | +135.76% |
| 2017-12-31 | $7.62 Million | -12.41% |
| 2016-12-31 | $8.70 Million | -11.35% |
| 2015-12-31 | $9.81 Million | +817.36% |
| 2014-12-31 | $1.07 Million | +3713.53% |
| 2013-12-31 | $-29.60K | -103.57% |
| 2012-12-31 | $830.00K | +59.62% |
| 2011-12-31 | $520.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CohBar Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9661927000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.91K | 0.02% |
| Other Components | $112.24 Million | 732.05% |
| Total Equity | $15.33 Million | 100.00% |
CohBar Inc Competitors by Market Cap
The table below lists competitors of CohBar Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Retail Food Group Limited
PINK:RFGPF
|
$1.34 Million |
|
Genix Pharmaceuticals Corporation
OTCQB:GENPF
|
$1.34 Million |
|
TronicS Microsystems SA
PA:ALTRO
|
$1.34 Million |
|
Capitol Nusantara Indonesia
JK:CANI
|
$1.34 Million |
|
BAINS MER MONAC N
MU:RJ8
|
$1.34 Million |
|
Australian Pacific Coal Ltd
AU:AQC
|
$1.34 Million |
|
iCoreConnect Inc. Common stock
NASDAQ:ICCT
|
$1.34 Million |
|
PortfolioMan Lundgr Inv-China kl n EUR
CO:PMILGICHIEUR
|
$1.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CohBar Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 25,607,827 to 15,332,029, a change of -10,275,798 (-40.1%).
- Net loss of 11,962,119 reduced equity.
- Dividend payments of 68 reduced retained earnings.
- Share repurchases of 68 reduced equity.
- New share issuances of 216,393 increased equity.
- Other factors increased equity by 1,470,064.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.96 Million | -78.02% |
| Dividends Paid | $68.00 | -0.0% |
| Share Repurchases | $68.00 | -0.0% |
| Share Issuances | $216.39K | +1.41% |
| Other Changes | $1.47 Million | +9.59% |
| Total Change | $- | -40.13% |
Book Value vs Market Value Analysis
This analysis compares CohBar Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.26x to 0.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $2.06 | $0.54 | x |
| 2013-12-31 | $0.00 | $0.54 | x |
| 2014-12-31 | $0.03 | $0.54 | x |
| 2015-12-31 | $9.19 | $0.54 | x |
| 2016-12-31 | $7.88 | $0.54 | x |
| 2017-12-31 | $6.10 | $0.54 | x |
| 2018-12-31 | $13.06 | $0.54 | x |
| 2019-12-31 | $5.70 | $0.54 | x |
| 2020-12-31 | $11.36 | $0.54 | x |
| 2021-12-31 | $11.53 | $0.54 | x |
| 2022-12-31 | $5.29 | $0.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CohBar Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -78.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-78.02%) is above the historical average (-96.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -177.24% | 0.00% | 0.00x | 1.08x | $-1.55 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-869.68K |
| 2014 | -170.13% | 0.00% | 0.00x | 1.84x | $-1.93 Million |
| 2015 | -39.52% | 0.00% | 0.00x | 1.08x | $-4.86 Million |
| 2016 | -69.84% | 0.00% | 0.00x | 1.10x | $-6.94 Million |
| 2017 | -129.06% | 0.00% | 0.00x | 1.16x | $-10.60 Million |
| 2018 | -87.44% | 0.00% | 0.00x | 1.28x | $-17.50 Million |
| 2019 | -167.75% | 0.00% | 0.00x | 1.66x | $-14.46 Million |
| 2020 | -79.16% | 0.00% | 0.00x | 1.19x | $-16.48 Million |
| 2021 | -60.17% | 0.00% | 0.00x | 1.07x | $-17.97 Million |
| 2022 | -78.02% | 0.00% | 0.00x | 1.07x | $-13.50 Million |
Industry Comparison
This section compares CohBar Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CohBar Inc (CWBR) | $9.50 Million | -177.24% | 0.32x | $1.34 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |